Novel GABAAR-α6 Subtype Selective Ligands for Pain and CNS Disorders
Safe and metabolically stable novel GABA A receptor ligands specific to the alpha 6 subtype (GABAAR-α6) for CNS disorders and pain.
Published: 8th September 2020

IP Status
- Patent application submitted
Seeking
- Development partner
- Licensing